Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 2004

View Archived Issues

Artekin may contribute to control of multidrug-resistant malaria

Enrollment complete in phase IV Visicol constipation study

Preclinical evidence for the antiviral efficacy of interferon alpha in SARS

Duloxetine improves voiding and quality of life of women with stress urinary incontinence

Clinical development of CAB-175 discontinued

Genzyme to acquire Ilex Oncology

Reorganization of indiplon agreements

Active Biotech discontinues discovery projects, focuses on development

Biovail acquires rights to novel formulations of eprosartan and carvedilol

Reolysin program update

Integrin alphavbeta3 antagonist and bone resorption inhibitor characterized for further development

Randomization completed in candesartan diabetic retinopathy program

Pharmacological characterization of novel DPP IV inhibitor K-579

Successful completion of first phase I trial for nebulized rAAT

Identification of neural stem cells in adult human brain

Improved response found in vitiligo patches with tacrolimus and excimer laser

Four related series of LDL receptor upregulators presented by GSK

New antibacterial oxazolidinones presented by Orchid researchers

Novel HDAC inhibitors prepared and tested by 4SC and G2M scientists

New glucosylceramide synthase inhibitors identified at Oxford Glycosciences

Aventis claims the preparation and use of novel cysteine protease inhibitors

New xanthine oxidase inhibitors for inflammation, reperfusion disorders and gout

Uriach presents immunomodulators and proapoptotic agents in a recent patent

Two novel series of glycogenphosphorylase a inhibitors under study at Aventis

Sinus and Allergy Health Partnership guidelines recommend Omnicef

Kirin announces phase I clinical trial of KRN-125 and other recent developments

Preclinical data supports use of INGN-241 regimens for lung, breast cancer

Satraplatin shows in vitro efficacy in tumor cells resistant to Taxotere and Taxol

Advanced Viral Research reports in vitro biologic effects of AVR-118

Approvable letter for Estorra

Zadaxin shows efficacy in preclinical invasive aspergillosis study

Investigation of Viagra for FSAD to close

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...